DGAP-News: Sangui BioTech International Inc.: Wound management specialist dealer will distribute Granulox in Switzerland
(firmenpresse) - DGAP-News: Sangui BioTech International Inc. / Key word(s): Alliance
Sangui BioTech International Inc.: Wound management specialist dealer
will distribute Granulox in Switzerland
08.10.2013 / 16:45
---------------------------------------------------------------------
Wound management specialist dealer will distribute Granulox in Switzerland
SastoMed GmbH and Agentur Scherrer GmbH sign agreement
Witten, Germany, October 8, 2013
In Switzerland the wound therapeutic Granulox is going to be distributed by
Agentur Scherrer GmbH (http://www.stomocur.ch) located in Weite, canton St.
Gallen. The specialist wholesale dealer focused on wound and stoma care
products signed an agreement to this effect with SastoMed GmbH, the global
licensee for this product.
Agentur Scherrer distributes a wide range of innovative and effective
products in the wound, stoma and fistula care segments including products
under the Polymem, CUREA and XTRATA brands. Its customer base includes
pharmacies, drug stores and users in all Swiss cantons.
Doris Scherrer, General Manager of Agentur Scherrer, explains: 'For our
business Granulox is more than just another complementation of our wound
management product portfolio. Thanks to its proven effectiveness we expect
significant attention and demand by patients and medical and care
professionals throughout the country.'
'Agentur Scherrer is a well established and successful specialist wholesale
dealer the sales network of which embraces all of Switzerland,' says
Michael Sander, the Managing Director of SastoMed. 'The agreement with
Scherrer gives us access to another interesting market in central Europe.
By now Granulox is represented in eleven European and two Latin American
countries with a total of around 300 million inhabitants. More agreements
covering additional markets are expected to follow suit in due course.'
Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing(at)sangui.de
End of financial news
---------------------------------------------------------------------
08.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
233798 08.10.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Miranda Gold Corp.: A New Drill Target Developing at Miranda's Pavo Real Project
Datum: 08.10.2013 - 16:45 Uhr
Sprache: Deutsch
News-ID 303922
Anzahl Zeichen: 3556
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 296 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Sangui BioTech International Inc.: Wound management specialist dealer will distribute Granulox in Switzerland"
steht unter der journalistisch-redaktionellen Verantwortung von
Sangui BioTech International Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
